Please login to the form below

Not currently logged in
Email:
Password:

cell therapy

This page shows the latest cell therapy news and features for those working in and with pharma, biotech and healthcare.

GSK hands rare disease assets over to Orchard

GSK hands rare disease assets over to Orchard

Those target mucopolysaccharidosis type 1 (MPS1 or Hurler syndrome), chronic granulomatous disease (CGD) and globoid cell leukodystrophy (GLD). ... GSK isn’t exiting cell and gene therapy entirely, as it will continue to work on developing a platform

Latest news

  • Celgene boosts CAR-T stake again with Bluebird Bio deal Celgene boosts CAR-T stake again with Bluebird Bio deal

    Mere weeks after completing its acquisition of CAR-T specialist Juno, Celgene has added to its cell therapy pipeline with another clinical-stage CAR-T candidate from Bluebird Bio. ... well as a pipeline of other cell and gene therapy candidates.

  • Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

    Takeda’ s Alofisel becomes Europe’ s first allogeneic stem cell therapy. ... Dr Asit Parikh, head of gastroenterology therapeutic area unit at Takeda, said: “Today’s marketing authorisation, the first for an allogeneic stem cell therapy,

  • Seattle Genetics claims key US approval for Adcetris Seattle Genetics claims key US approval for Adcetris

    Last November it was granted FDA approval in adult patients with cutaneous T cell lymphoma (CTCL) and there is more to come. ... The company is also waiting for the results of the ECHELON-2 trial of Adcetris as a first-line therapy for peripheral T cell

  • Gilead signs $3bn-plus gene-editing deal with Sangamo Gilead signs $3bn-plus gene-editing deal with Sangamo

    Gilead signs $3bn-plus gene-editing deal with Sangamo. Will use the platform for new cell-based cancer therapies. ... Gilead Sciences has claimed another stake in the emerging cell therapy sector with a $3bn agreement to use Sangamo Biosciences

  • AZ expects return to growth this year after 2017 decline AZ expects return to growth this year after 2017 decline

    The contribution of these drugs as well as blockbuster sales for antiplatelet therapy Brilinta (ticagrelor) and diabetes drug Farxiga (dapagliflozin) allowed AZ to boost operating profit by 2% to $6.86bn ... Mantle cell lymphoma therapy Calquence has a

More from news
Approximately 5 fully matching, plus 160 partially matching documents found.

Latest Intelligence

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    CAR-T cell therapy for children with B-cell ALL. ... costs. It was then backed with a ‘no response-no payment’contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... A few days later Takeda announced it was paying $628m (82% share price premium) to buy Belgian company TiGenix NV and its lead asset Cx601 (darvadstrocel),

  • A unique ecosystem A unique ecosystem

    Regenerative medicine aims to repair injuries or diseased organs using biomaterials, gene therapy, cell therapy and tissue engineering.

  • Boosting pharma’s metabolic rate Boosting pharma’s metabolic rate

    New frontiers such as cell therapy and RNAi are becoming therapeutic realities and exciting new challenges are coming over the horizon, creating a constantly shifting landscape that leaders must navigate. ... Recent commercial partnerships in the cell

  • Pharma deals continue to slide Pharma deals continue to slide

    This referred to the CAR-T therapy, Kymriah, from Novartis for treating a form of acute lymphoblastic leukaemia in children and young adults. ... 425 (upfront 80). Calimmune (US). CSL (AU). Company acquisition. Preclinical haematopoietic stem cell

More from intelligence
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest appointments

  • Zelluna Immunotherapy appoints chief technology officer Zelluna Immunotherapy appoints chief technology officer

    Arjan Roozen, who previously headed up the GMP solutions and manufacturing team at French cell therapy group Cellectis, comes with expertise in microbiology and molecular microbiology. ... Miguel Forte, chief executive officer of Zelluna, said:

  • Celgene boosts CAR-T stake again with Bluebird Bio deal Celgene boosts CAR-T stake again with Bluebird Bio deal

    Mere weeks after completing its acquisition of CAR-T specialist Juno, Celgene has added to its cell therapy pipeline with another clinical-stage CAR-T candidate from Bluebird Bio. ... well as a pipeline of other cell and gene therapy candidates.

  • Bone Therapeutics strengthens board with new chairman Bone Therapeutics strengthens board with new chairman

    Bone Therapeutics strengthens board with new chairman. Jean Stéphenne joins the cell therapy company from TiGenix. ... He will be a valuable addition to an already strong board as we advance our allogeneic cell therapy platform through clinical

  • Zelluna appoints Miguel Forte as CEO Zelluna appoints Miguel Forte as CEO

    Forte’s expertise is predominantly in regenerative medicine, cell therapy, medical and regulatory affairs industries and is currently chief commercialisation officer and chair of the commercialisation committee for the International Society

  • Orchard Therapeutics appoints Mark Rothera as CEO Orchard Therapeutics appoints Mark Rothera as CEO

    He said: “Now is an exciting time to be joining Orchard as the cell and gene therapy field is advancing successfully. ... The clinical data we’ve seen to date with Orchard’s therapy for ADA-SCID is exceptional, and the company has assembled and

More from appointments
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics